Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Jackson

Clinical Nurse Specialist, Adult Health Temple, TX Clinical Nurse Specialist

NPI 1659696003 CMS profile 10750377

2401 S 31St St, Temple, TX 76508

Open in the dashboard

General payments

$22,327

332 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Jackson of Temple, TX is reported in the CMS Open Payments database as having received $22,327 across 332 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $620 19
2024 General $1,227 34
2023 General $962 36
2022 General $13,170 140
2021 General $6,349 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Jackson
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Elizabeth Jackson were reported at $620. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Elizabeth Jackson Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $6,349 $133 $48–$445 $132
2022 $13,170 $163 $57–$526 $149
2023 $962 $173 $64–$597 $160
2024 $1,227 $171 $54–$575 $164
2025 $620 $193 $61–$597 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Esperion Therapeutics, Inc. $12,364 51 payments
  2. Regeneron Healthcare Solutions, Inc. $3,203 21 payments
  3. Novartis Pharmaceuticals Corporation $2,370 80 payments
  4. Amgen Inc. $923 32 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $576 23 payments
  6. Novo Nordisk Inc $530 13 payments
  7. Pfizer Inc. $390 22 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $348 19 payments
  9. AstraZeneca Pharmaceuticals LP $338 17 payments
  10. Regeneron Pharmaceuticals, Inc. $219 4 payments
  11. Other $1,068 50 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,830 7 payments
  2. Food and Beverage $8,537 303 payments
  3. Travel and Lodging $2,790 18 payments
  4. Consulting Fee $2,170 4 payments
Products named General payments · program years 2021–2025
  1. NEXLETOL $12,364 51 payments
  2. NEXLIZET $11,739 37 payments
  3. EVKEEZA $3,290 24 payments
  4. LEQVIO Cardiology/Vascular Diseases $816 32 payments
  5. LEQVIO Cardiovascular $782 10 payments
  6. Repatha $693 26 payments
  7. ENTRESTO $642 36 payments
  8. Ozempic $530 13 payments
  9. JARDIANCE $516 20 payments
  10. LifeVest $348 19 payments
  11. Other $3,021 146 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,681

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$743,055

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

37.1%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 156 $209,450
Mounjaro Tirzepatide Brand 111 $135,066
Repatha Sureclick Evolocumab Brand 113 $128,368
Jardiance Empagliflozin Brand 60 $92,172
Farxiga Dapagliflozin Propanediol Brand 35 $40,729
Praluent Pen Alirocumab Brand 23 $27,741
Repatha Syringe Evolocumab Brand 17 $22,354
Eliquis Apixaban Brand 17 $21,606
Wegovy Semaglutide Brand 14 $18,904
Vascepa Icosapent Ethyl Brand 16 $12,959

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$17,499

Medicare's payments for the services billed

Medicare patients

134

Average age 69

Services billed

240

73 women, 61 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Diabetes 53%
Arthritis 46%
Chronic kidney disease 35%
Heart failure 29%
Depression 22%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $394
$394 — —
Repatha
  • Amgen Inc. $274
$274 130 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $52
$52 35 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $38
$38 60 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

332 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record